methoxypsoralen
Phase 3Small molecule
methoxypsoralen is one of 49 small molecule programs targeting Mycosis Fungoides. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Mycosis Fungoides
#DrugCompanyPhaseTrials
1Arranon
NovartisApproved
Istodax
TevaApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Adcetris
PfizerPhase 2
Keytruda
Merck & Co.Phase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Mycosis Fungoides1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for methoxypsoralen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details